CJC-1295 vs Sermorelin: GHRH Analog Comparison

CJC-1295 vs Sermorelin: GHRH Analog Comparison CJC-1295 vs sermorelin compared: GHRH analogs, DAC half-life advantage, dosing frequency, GH pulsatility, evidence grades, cost, and research applications. CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog available in two forms: with DAC (Drug Affinity Complex) providing an extended 8-day half-life for sustained GH elevation, and without DAC (mod-GRF 1-29) for pulsatile GH release. Sermorelin is the first 29 amino acids of natural GHRH, previously FDA-approved for pediatric growth hormone deficiency, with the most human clinical data among GHRH analogs. Both stimulate endogenous GH production through the GHRH receptor but differ significantly in half-life, dosing frequency, and GH release patterns. Mechanism GHRH receptor agonist (synthetic analog) GHRH receptor agonist (natural GHRH 1-29) Evidence Grade B+ A- Half-Life ~8 days (with DAC); ~30 min (no DAC) ~10-20 minutes Route Subcutaneous injection Typical Dose 2 mg/week (DAC); 100 mcg 2-3x/day (no DAC) 200 - 300 mcg before bed daily GH Release Pattern Sustained elevation (DAC); pulsatile (no DAC) Pulsatile (mimics natural secretion) Dosing Frequency 2-3x/week (DAC); daily (no DAC) Daily (typically before bed) Best For Sustained IGF-1 elevation, convenience Natural GH pulsatility, clinical-grade research FDA Status Not FDA-approved; research compound Previously FDA-approved (Geref); withdrawn 2008 Cost (research grade) $$ $ Extended half-life (DAC) allows 2-3x/week dosing Sustained GH and IGF-1 elevation Strong synergy when combined with GHRP peptides Mod-GRF 1-29 (no DAC) preserves pulsatile release Well-tolerated in clinical studies DAC version may desensitize GH receptors over time Less human clinical data than sermorelin Sustained GH elevation (DAC) is non-physiological Not FDA-approved in any formulation Higher cost than sermorelin at research grade Previously FDA-approved with extensive human safety data Natural pulsatile GH release pattern Available through compounding pharmacies Lowest cost GHRH analog Best-characterized pharmacokinetics in humans Preserves hypothalamic-pituitary feedback Very short half-life requires daily injection Weaker GH pulse amplitude than CJC-1295 (no DAC) Requires consistent bedtime dosing for optimal results Some users develop antibodies with long-term use Withdrawn from market (commercial, not safety reasons) Choose CJC-1295 with DAC if: Your research prioritizes convenience and sustained GH/IGF-1 elevation. The 8-day half-life allows infrequent dosing and provides steady-state GH levels. Best suited for protocols where consistent anabolic signaling is more important than preserving natural pulsatile secretion. Choose CJC-1295 without DAC (mod-GRF 1-29) if: You want stronger GH pulse amplitude than sermorelin while maintaining pulsatile release. Often paired with a GHRP (like ipamorelin) for synergistic GH secretion. This is the most popular research GHRH analog for combined protocols. Choose sermorelin if: You prioritize the deepest human safety data, natural physiological GH pulsatility, and the lowest cost. Sermorelin's FDA history and compounding pharmacy availability make it the most accessible and well-characterized GHRH analog for clinical research. CJC-1295 with DAC produces more sustained GH elevation due to its 8-day half-life. Sermorelin mimics natural pulsatile GH release better. CJC-1295 without DAC (mod-GRF 1-29) provides stronger GH pulses than sermorelin while maintaining pulsatility. The choice depends on whether sustained or pulsatile GH release is desired for your research. CJC-1295 with DAC binds to albumin, extending half-life to ~8 days with sustained, non-pulsatile GH elevation. Without DAC (mod-GRF 1-29) has a 30-minute half-life producing discrete GH pulses. The DAC version requires less frequent dosing but may desensitize receptors, while the non-DAC version preserves natural pulsatile patterns. Yes, sermorelin (Geref) was FDA-approved in 1997 for diagnostic use and pediatric GH deficiency treatment. It was voluntarily withdrawn in 2008 for commercial reasons, not safety concerns. It remains available as a compounded peptide and has the most human clinical data of any GHRH analog. Verified Research Suppliers ★ LiveWell Peptides — Preferred Vendor • cGMP Certified Preferred vendor Core Peptides — Third-party tested — Broad catalog Biotech Peptides — USA-based Related Tools & Resources Related Resources